Research

Cellular

Higher maximum semaglutide dose was associated with lower post-landmark risk of all-cause mortality (RR 0.42, p<0.001) and composite cardiovascular events (RR 0.51, p<0.001).

Practitioners should consider maximizing semaglutide dosage to enhance cardiovascular outcomes.

StrongSupportsmedium confidence
Higher maximum semaglutide dose was associated with... lower post-landmark risk of all-cause mortality (RR 0.42, p<0.001), composite cardiovascular events (death, myocardial infarction, or stroke; RR 0.51, p<0.001).
Karthik Murugadoss et al. · medRxiv · 2026

Why this rating

Based on the analysis of a large cohort of semaglutide-treated individuals.

Source

Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss

Karthik Murugadoss et al. · medRxiv · 2026

DOI 10.64898/2026.04.02.26350077

cohort · n=505874Cited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →